#None #Inc. #Bioscience #Avantor #Medtech Products

Avantor® Reports First Quarter 2026 Results

Avantor, Inc. (NYSE: AVTR), a prominent global provider of mission-critical products and services, released its financial results for the first fiscal quarter ending March 31, 2026. The results indicate a demand for their offerings continues, even with some operational hurdles.

In the first quarter of 2026, Avantor reported net sales amounting to $1,581.4 million, showing a slight decrease from $1,581.4 million in the same period of 2025. However, the impact of foreign currency translation positively affected results by 4.1%, indicating robust international engagement. On an organic basis, sales saw a decline of 4.1%.

Financial Highlights

• - Net Income: Avantor's net income was reported at $43.3 million, down from $64.5 million recorded in Q1 2025, reflecting a net income margin of 2.7%.
• - Adjusted Earnings: The adjusted net income for the quarter was $114.0 million, compared to $155.2 million in the same timeframe last year.
• - EBITDA: The adjusted EBITDA stood at $219.4 million, maintaining an adjusted EBITDA margin of 13.9%.
• - Operating Cash Flow: Operating cash flow was reported at $58.7 million, with free cash flow amounting to $25.2 million.

Emmanuel Ligner, President and CEO, commented, "Our first-quarter results surpassed expectations primarily due to enhanced execution in our Bioscience and Medtech product lines. Additionally, we are beginning to observe stabilization within our VWR segment.” He expressed optimism regarding the organization's ongoing revival process.

Segment Analysis

Avantor’s operations encompass various segments, and each provided insight into performance:

• - VWR Distribution Services: Net sales were $1,150.0 million, reflecting a slight decline of 0.4% compared to the previous year. Here, foreign currency had a positive effect of 4.4%, resulting in a 4.8% organic sales decline. Adjusted operating income was $105.4 million, down from $147.9 million.

• - Bioscience and Medtech Products: This segment emerged with net sales of $431.4 million, an increase of 1.2% year-on-year. Adjusted operating income was $102.7 million, showcasing a margin of 23.8%. The underlying trends observed here reflect healthy demand for innovative healthcare solutions.

2026 Guidance

Avantor has reiterated its guidance for fiscal year 2026, indicating stability within its operational aspirations. The company has effectively communicated its aim to not only meet but exceed the baseline expectations set during the previous financial year.

Future Outlook

In light of the current financial landscape, Avantor continues its commitment to evaluating performance through both GAAP and non-GAAP financial measures. The analytical approach adopted allows for a deeper understanding of operational efficiencies and underlying trends in business segments, thus equipping investors with realistic forecasts regarding future performance.

A conference call was scheduled on April 29, 2026, to discuss these results further, welcoming investor observations and inquiries.

About Avantor

Avantor is a leader in life science tools and services, providing a broad array of products essential to the life sciences and advanced technology sectors. The extensive portfolio touches every phase of significant research, development, and production efforts at over 300,000 customer locations worldwide, across 180 countries. The commitment to innovation positions Avantor at the forefront of industry advancements while fostering partnerships that drive discovery and application.

To explore more detailed performance metrics or investment inquiries, visit corporate.avantorsciences.com or connect with us on social media platforms such as LinkedIn and Twitter.